^
Association details:
| Biomarker: | CPE-ALK fusion + TP53 wild-type |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
Published date:
12/01/2022
Excerpt:
Here we describe the case of a stage IV ASC patient harboring a novel CPE-ALK fusion detected via 74 genes panel analysis. Interestingly, the TP53 was wild-type and no another somatic mutation was found within 74 genes….the patient received alectinib 600 mg twice daily. After 4 months on treatment the patients achieved a radiological partial response (PR) and his symptoms were significantly relieved.
DOI:
https://doi.org/10.3389/fonc.2022.998545
